You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK):將推動BGB-11417潛在註冊可用2期研究臨床開發
百濟神州(06160.HK)公布,日前在2023年歐洲血液學協會(EHA)年會上展示旗下早期管線產品的最新研究數據,當中百悅澤獲數據支持,總體耐受性良好,相關不良事件的嚴重程度通常為輕度至中度,通常不會導致治療終止。 此外研究數據顯示,BCL-2抑制劑產品BGB-16673BGB-11417在治療難治性(R/R)慢性淋巴細胞白血病(CLL)及小淋巴細胞淋巴瘤(SLL)患者時,顯示出良好的初步療效結果,患者在較低劑量水準下達到緩解。公司表示,初步療效結果良好,將繼續推動BGB-11417用於治療R/R套細胞淋巴瘤(MCL)及R/R CLL及SLL的潛在註冊可用2期研究的臨床開發。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account